192 related articles for article (PubMed ID: 25359717)
1. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
Edwards MA; Crombie K; Schramm C; Krenz M
J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
[TBL] [Abstract][Full Text] [Related]
2. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
3. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Krenz M; Yutzey KE; Robbins J
Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
[TBL] [Abstract][Full Text] [Related]
4. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
Roy R; Krenz M
J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
[TBL] [Abstract][Full Text] [Related]
5. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
[TBL] [Abstract][Full Text] [Related]
6. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
7. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
[TBL] [Abstract][Full Text] [Related]
8. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
9. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
[TBL] [Abstract][Full Text] [Related]
10. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
Yi JS; Perla S; Enyenihi L; Bennett AM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
[TBL] [Abstract][Full Text] [Related]
11. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
13. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
14. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
15. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
[TBL] [Abstract][Full Text] [Related]
16. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
17. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.
Hartman ZR; Schaller MD; Agazie YM
Mol Cancer Res; 2013 Jun; 11(6):651-64. PubMed ID: 23512980
[TBL] [Abstract][Full Text] [Related]
19. Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2.
Khare S; Holgren C; Samarel AM
Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1100-12. PubMed ID: 16920701
[TBL] [Abstract][Full Text] [Related]
20. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.
Tajan M; Batut A; Cadoudal T; Deleruyelle S; Le Gonidec S; Saint Laurent C; Vomscheid M; Wanecq E; Tréguer K; De Rocca Serra-Nédélec A; Vinel C; Marques MA; Pozzo J; Kunduzova O; Salles JP; Tauber M; Raynal P; Cavé H; Edouard T; Valet P; Yart A
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4494-503. PubMed ID: 25288766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
